| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/22/2004 | CA2500742A1 Compositions of fgf-18 and hyaluronic acid for stimulating cartilage production and treating osteoarthritis |
| 04/22/2004 | CA2500665A1 Methods of regulating body weight |
| 04/22/2004 | CA2500310A1 Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics |
| 04/22/2004 | CA2499351A1 Alkoxylates exhibiting low residual alcohol content |
| 04/22/2004 | CA2498938A1 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| 04/22/2004 | CA2494104A1 Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| 04/22/2004 | CA2465860A1 Methods and compositions for therapeutic use of rna interference |
| 04/21/2004 | EP1411075A2 Method for preparing polymer conjugates |
| 04/21/2004 | EP1410806A1 Remedies for mammary cancer |
| 04/21/2004 | EP1410805A1 Vaccine against HPV |
| 04/21/2004 | EP1410797A1 Solid oral dosage forms comprising valsartan |
| 04/21/2004 | EP1410791A1 Orally administrable galenic form comprising metformine and an absorption-promoting agent |
| 04/21/2004 | EP1409710A1 Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer |
| 04/21/2004 | EP1409701A2 Fluorescently labelled locked nucleic acids |
| 04/21/2004 | EP1409668A2 Antisense nucleic acid against alphav integrin |
| 04/21/2004 | EP1409645A1 Probiotic lactobacillus salivarius strains |
| 04/21/2004 | EP1409644A1 Probiotic bifidobacterium strains |
| 04/21/2004 | EP1409621A1 8-tetradecenal serving as an odorous or aromatic substance |
| 04/21/2004 | EP1409602A1 Pyrrolidonoethyl (meth) acrylate containing pressure sensitive adhesive compositions |
| 04/21/2004 | EP1409549A2 Compositions and methods for the diagnosis and treatment of tumor |
| 04/21/2004 | EP1409548A2 Ligands to enhance cellular uptake of biomolecules |
| 04/21/2004 | EP1409519A1 Lipid-peptide conjugates for treatment of cancer |
| 04/21/2004 | EP1409482A2 Dye-sulfenates for dual phototherapy |
| 04/21/2004 | EP1409077A2 Thermotherapy via targeted delivery of nanoscale magnetic particles |
| 04/21/2004 | EP1409076A2 Method and apparatus for treating tumors using low strength electric fields |
| 04/21/2004 | EP1409034A1 Topical pharmaceutical formulation |
| 04/21/2004 | EP1409026A1 Kit for intraperitoneal administration and extracorpeal removal of a drug |
| 04/21/2004 | EP1409024A1 Macrocyclic metal complexes and use thereof for production of conjugates with biomolecules |
| 04/21/2004 | EP1409023A1 Compositions and preparation methods for bioavailable oral aceaceclofenac dosage forms |
| 04/21/2004 | EP1409022A1 Pharmaceutical vehicle |
| 04/21/2004 | EP1409021A2 Formulation comprising fulvestrant |
| 04/21/2004 | EP1409018A2 Stable lyophilized pharmaceutical formulation of igg antibodies |
| 04/21/2004 | EP1409017A2 Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications |
| 04/21/2004 | EP1409006A2 Methods of treating diabetes mellitus |
| 04/21/2004 | EP1408999A1 Compositions addressing inflammation and/or degenerative disorders |
| 04/21/2004 | EP1408982A1 Pharmaceutical compositions for treatment of digestive disorders and associated diseases |
| 04/21/2004 | EP1408967A2 Novel pharmaceutical compositions based on anticholinergic agents, corticosteroids and betamimetic agents for the treatment of inflammatory and/or obstructive respiratory tract diseases |
| 04/21/2004 | EP1408956A1 Uses of metal salts to stabilize taxane-based compositions |
| 04/21/2004 | EP1408951A2 Anti-inflammatory fatty alcohols and fatty acid esters useful as antigen carriers |
| 04/21/2004 | EP1408947A2 Fumaric acid derivatives as nf-kappab inhibitors |
| 04/21/2004 | EP1408943A2 Pharmaceutical formulation containing an ltb4 antagonist |
| 04/21/2004 | EP1408942A1 Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
| 04/21/2004 | EP1408930A1 Microemulsion preconcentrates which contain cyclosporines and corresponding microemulsions |
| 04/21/2004 | EP1408929A2 Ophthalmic composition containing n-acetylcysteine for the treatment of dry-eye syndrom |
| 04/21/2004 | EP1408911A1 Sustained-release therapeutic bioadhesive systems |
| 04/21/2004 | EP1408908A2 Compositions and methods for inhibition of cancer invasion and angiogenesis |
| 04/21/2004 | EP1408897A2 Gum resin as a carrier for topical application of pharmacologically active agents |
| 04/21/2004 | EP1408876A1 Zero-order prolonged release coaxial implants |
| 04/21/2004 | EP1408768A1 SUGAR-FREE HARD COATINGS PREPARED FROM LIQUID MALTITOL COMPRISING DP sb 4+ /sb FRACTION |
| 04/21/2004 | EP1408757A2 Method and composition for prolonging the residence time of drugs in the gut |
| 04/21/2004 | EP1408750A2 A cream-t0-powder dermatological composition |
| 04/21/2004 | EP1313498A4 Phospholipase d effectors for therapy and screening |
| 04/21/2004 | EP1267900B1 Emulsion containing a triterpen containing plant extract, method for producing said emulsion and for obtaining a plant extract |
| 04/21/2004 | EP1183016B1 Stereocomplex hydrogels |
| 04/21/2004 | EP1181036A4 Pharmaceutical compositions of erythropoietin |
| 04/21/2004 | EP1178783B1 Device and use for increasing the transdermal permeation of medicaments |
| 04/21/2004 | EP1121099B1 Pharmaceutical composition with gastric residence and controlled release |
| 04/21/2004 | EP0941095B1 Improved pharmaceutical compositions |
| 04/21/2004 | EP0918543B1 Polymer composition for oral administration of peptides and proteins |
| 04/21/2004 | EP0900379B1 Receptor for underivatized, aqueous soluble beta(1-3)-glucan |
| 04/21/2004 | EP0836647B1 Antiviral proteins, dna coding sequences therefor, and uses thereof |
| 04/21/2004 | EP0746327B1 Acidified nitrite as an antimicrobial agent |
| 04/21/2004 | EP0693924B1 Methods for (in vivo) delivery of biologics and compositions useful therefor |
| 04/21/2004 | CN1491232A Modified leptin with reduced immunogenicity |
| 04/21/2004 | CN1491231A Modified keratinocyte growth factor (KGF) with reduced immunogenicity |
| 04/21/2004 | CN1491117A Compositions containing inclusion complexes |
| 04/21/2004 | CN1491115A Use of botulinum toxin for treatment of articular pathologies |
| 04/21/2004 | CN1491114A Compositions for nasal administration of insulin |
| 04/21/2004 | CN1491108A Antifungal remedy formulation for external application |
| 04/21/2004 | CN1491105A Novel modified released formulation |
| 04/21/2004 | CN1491104A Novel modified release formulation |
| 04/21/2004 | CN1491089A Composition and method for smoke detoxification |
| 04/21/2004 | CN1490056A Immune method and composition for HIV-1 |
| 04/21/2004 | CN1490055A Method for preparing nanometre structure medicine |
| 04/21/2004 | CN1490048A Method for improving oral drug living thing availability, composition and reagent box |
| 04/21/2004 | CN1146429C Phospholipid complexes of proanthocyanidin A2 used as antiatherosclerotic agent |
| 04/21/2004 | CN1146428C Crystallized pirimiphos-methyl composite and its preparation and usage |
| 04/21/2004 | CN1146426C Stable aspirin-containing preparations for external use |
| 04/21/2004 | CN1146424C Stabilized tibolone compositions |
| 04/21/2004 | CN1146423C Prostaglandin product |
| 04/21/2004 | CN1146419C Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
| 04/21/2004 | CN1146418C Fixed-dose association of angiotensin-converting enzyme inhibitor and of calcium channel antagonist, method for preparation and use thereof in treatment of cardivas cular illnesses |
| 04/21/2004 | CN1146417C Stabilized pharmaceutical compositions, with quinupristine and dalfopristine base and their prepn |
| 04/21/2004 | CN1146413C Pharmaceutical composition for injection based on paracetamol |
| 04/21/2004 | CN1146410C Controlled release formulation |
| 04/21/2004 | CN1146409C Fast decomposing pellets |
| 04/21/2004 | CN1146408C Novel poly(methylidene malonate) microspheres, preparation method and pharmaceutical compositions containing them |
| 04/21/2004 | CN1146405C Free-flowing dried particles |
| 04/21/2004 | CN1146404C Opthalmic solution comprising glycogen |
| 04/21/2004 | CN1146402C Gel composition and method of preparing the composition |
| 04/20/2004 | US6723893 Mice having a mutant SOD-1-encoding transgene |
| 04/20/2004 | US6723867 Branched, substantially unsaturated fatty alcohol sulfates |
| 04/20/2004 | US6723831 Removal antibodies from body fluids |
| 04/20/2004 | US6723788 Enzyme inhibitors |
| 04/20/2004 | US6723755 Method of treating rosacea |
| 04/20/2004 | US6723732 Percutaneously adminstrable preparations containing cerebral function activators |
| 04/20/2004 | US6723714 Aqueous solvent for corticosteroids |
| 04/20/2004 | US6723708 Lithium chloride |
| 04/20/2004 | US6723538 Therapy for infections, immunology diseases |
| 04/20/2004 | US6723497 Therapeutic platelets and methods |